自身免疫性皮肤科疾病的B细胞-靶向生物治疗  

B Cell-targeted Biologic Therapy for Autoimmune-mediated Dermatological Disorders

作　　者：林熙然[1] 黄畋[2] 

机构地区：[1]大连医科大学附属第一医院,辽宁大连116011 [2]大连医科大学附属第二医院,辽宁大连116027

出　　处：《中国皮肤性病学杂志》2010年第1期79-81,共3页The Chinese Journal of Dermatovenereology

摘　　要：B细胞靶向生物学疗法包括抗B细胞表面标记的抗体和B细胞存活和信号因子的抑制剂。抗CD20的利妥昔单抗去除B细胞最初用于B细胞淋巴瘤,现已由FDA批准治疗类风湿性关节炎,并有效地用于多种自身免疫性皮肤科疾病。B细胞在自身免疫中作用并不仅是产生自身抗体。进一步了解B细胞在自身免疫中的复杂作用将有助于研发具有更佳疗效和安全性的疗法。Currently introduced B cell targeted biologic therapies include antibodies against B cell-surface antigens and inhibitors of B cell survival and signaling factors. Initially introduced as a treatment for B cell lymphoma, rituximab, a monoclonal antibody that depletes B cells by binding to the CD20 antigen, is now approved for the treatment of rheumatoid arthritis by FDA and has been successfully used in treating a number of autoimmunemediated dermatological disorders. The appreciation of B cells in autoimmunity is not limited to autoantibody production. Further understanding the complex roles of B cells in autoimmunity will facilitate the development of agents with more efficacy and safety than those currently employed.

关 键 词：B细胞靶向生物学治疗 自身免疫性皮肤科疾病 

分 类 号：R733.4[医药卫生—肿瘤] R730.54[医药卫生—临床医学]